BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Myositis Support and Understanding - ECPv6.15.17//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Myositis Support and Understanding
X-ORIGINAL-URL:https://understandingmyositis.org
X-WR-CALDESC:Events for Myositis Support and Understanding
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240918T140000
DTEND;TZID=America/New_York:20240918T150000
DTSTAMP:20260416T011453
CREATED:20240904T192513Z
LAST-MODIFIED:20240905T153729Z
UID:10001868-1726668000-1726671600@understandingmyositis.org
SUMMARY:Innovative Approaches in Biopharmaceutical Research: Ensuring Patient-Centric Healthcare Solutions
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]In this webinar\, we’ll highlight the impactful collaboration between Galapagos and MSU\, focusing on our shared dedication to patient-centric healthcare. Our partnership has been vital in several initiatives\, including the collection of patient voices for our ongoing Phase 2 clinical trial. At Galapagos\, our research in inflammation and oncology is driven by a commitment to ensure that patient perspectives are central to our initiatives\, shaping solutions that truly meet patient needs and expectations. \nA significant aspect of our approach is the development of patient facing materials including informed consent documents. Zoltan Koleszar\, GLPG Patient Advocacy Leader\, will share his expertise on how patient recommendations are integrated into these critical documents. He will discuss how we ensure that the informed consent process is transparent\, comprehensible\, and respectful of patient needs\, and outline how these documents are approved for use in clinical trials. \nAdditionally\, we will feature a pre-recorded segment by Ann Fieuw\, GLPG Senior Medical Director. Ann will provide valuable insights into recent trends in dermatomyositis and information on our ongoing clinical trial. \nJoin us for this comprehensive session to understand how Galapagos is integrating patient feedback into every stage of research\, ensuring that our healthcare solutions are as effective and relevant as possible.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row][vc_row][vc_column] REGISTER[/vc_column][/vc_row]
URL:https://understandingmyositis.org/event/innovative-approaches-in-biopharmaceutical-research-ensuring-patient-centric-healthcare-solutions/
LOCATION:ZOOM Webinar\, 9125 N Old State Rd\, Lincoln\, DE\, 19960\, United States
CATEGORIES:Video Session
ATTACH;FMTTYPE=image/png:https://understandingmyositis.org/wp-content/uploads/2024/09/Galapagos-Webinar-Graphic.png
ORGANIZER;CN="Myositis Support and Understanding (MSU)":MAILTO:info@UnderstandingMyositis.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240930T140000
DTEND;TZID=America/New_York:20240930T150000
DTSTAMP:20260416T011453
CREATED:20240904T200058Z
LAST-MODIFIED:20240905T153827Z
UID:10001870-1727704800-1727708400@understandingmyositis.org
SUMMARY:Realizing the CAR T Potential in Myositis & Beyond
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]Cabaletta Bio is a clinical-stage biotechnology company focused on developing T cell therapies with potential to provide durable\, perhaps curative\, treatment for patients with autoimmune diseases. CABA-201\, a CD19-CAR T cell therapy\, is being evaluated in the RESET™ Phase 1/2 trials across several autoimmune diseases\, including adult and juvenile myositis. \nTania Gonzalez Rivera\, M.D.\, discusses the application of CAR-T cell therapy in treating myositis and delves into the mechanism of CAR-T therapy\, its successes\, challenges\, and future prospects in revolutionizing autoimmune disease treatment. \nDr. Gonzalez is a renowned physician and executive leader in the biotechnology industry. She currently serves as the Vice President of Medical Affairs at Cabaletta Bio\, a company dedicated to developing novel therapies for autoimmune diseases. Dr. Gonzalez completed her Doctor of Medicine and Residency at the University of Puerto Rico School of Medicine and her Rheumatology Fellowship at the University of Michigan Medical School. \nHer research and clinical expertise include autoimmune diseases\, particularly in the areas of rheumatology and dermatology. She has published numerous papers in peer-reviewed journals on topics such as psoriasis\, and lupus\, and presented research findings at major scientific conferences\, including the American Academy of Dermatology and the American College of Rheumatology.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row][vc_row][vc_column] REGISTER[/vc_column][/vc_row]
URL:https://understandingmyositis.org/event/realizing-the-car-t-potential-in-myositis-and-beyond/
LOCATION:ZOOM Webinar\, 9125 N Old State Rd\, Lincoln\, DE\, 19960\, United States
CATEGORIES:Video Session
ATTACH;FMTTYPE=image/png:https://understandingmyositis.org/wp-content/uploads/2024/09/Cabaletta-Bio.png
ORGANIZER;CN="Myositis Support and Understanding (MSU)":MAILTO:info@UnderstandingMyositis.org
END:VEVENT
END:VCALENDAR